Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for KERX
-0.18 (-2.30%)
Jul 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.29 - 8.02
52 week 7.29 - 18.48
Open 7.85
Vol / Avg. 1.61M/1.63M
Mkt cap 812.19M
P/E     -
Div/yield     -
EPS -1.34
Shares 103.60M
Beta 3.23
Inst. own 90%
Aug 5, 2015
Q2 2015 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 24, 2015
Keryx Biopharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 16, 2015
Keryx Biopharmaceuticals Inc Annual Shareholders Meeting
May 13, 2015
Keryx Biopharmaceuticals, Inc. at Bank of America Merrill Lynch 2015 Health Care Conference
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Release
May 4, 2015
Q1 2015 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2360.77% -1030.19%
Operating margin -2368.00% -1027.52%
EBITD margin - -1024.69%
Return on average assets -71.93% -135.67%
Return on average equity -91.94% -187.61%
Employees 155 -
CDP Score - -


750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxia's pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Gregory P. Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
James F. Oliviero III Chief Financial Officer, Treasurer, Corporate Secretary
Age: 39
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 74
Bio & Compensation  - Reuters